|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 27, 2017 ) The bladder cancer market in the seven major pharmaceutical markets (US France Germany Italy Spain UK and Japan) has remained largely unchanged in the past 10-20 years. However significant expansion is expected starting in 2016 with the introduction of several new therapies that are projected to fuel market growth. In addition bladder cancer has a robust early-stage pipeline that will contribute to market growth during the forecast period. Currently the bladder cancer market is dominated by generic chemotherapy and immunotherapy. Though initially effective toxicity and lack of clinical efficacy in improving overall survival have left the door open for more tolerable and effective drugs to be developed. In the past bladder cancer has not been an area of focus for pharmaceutical companies but that is rapidly changing as more companies focus on the bladder cancer market recognizing the high level of unmet need and relatively clear regulatory path. During the forecast period the market landscape will begin to change dramatically with the introduction of newer immunotherapies specifically PD-1 checkpoint modulators of which five are expected to launch by 2025. These drugs will provide much-needed alternatives to bladder cancer patients who have not benefitted from traditional treatments.
For more information about this report at http://www.reportsweb.com/opportunityanalyzer-bladder-cancer-opportunity-analysis-and-forecasts-to-2025
Scope
- Overview of bladder cancer including epidemiology etiology pathophysiology symptoms diagnosis and current management strategies.
- Topline Bladder cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include current treatment options unmet needs and opportunities and the drivers and barriers affecting bladder cancer therapeutics sales in the 7MM.
- Pipeline analysis comprehensive data split across different phases emerging novel trends under development synopses of innovative early-stage projects and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to-
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market.
- Drive revenues by understanding the key trends innovative products and technologies market segments and companies likely to impact the bladder cancer therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations investments and strategic partnerships.
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881607/sample
Table of Content
1.1 List of Tables 6
2 Bladder Cancer Executive Summary 10
3 Disease Overview 19
4 Epidemiology 27
5 Current Treatment Options 51
6 Unmet Needs Assessment and Opportunity Analysis 93
7 Research and Development Strategies 100
8 Pipeline Assessment 110
9 Pipeline Valuation Analysis 164
10 Appendix 187
Inquire for Report at http://www.reportsweb.com/inquiry&RW0001881607/buying
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
